Evidence map›Paper›PMID 33252634›Full record

ArticleInvestigative ophthalmology & visual science2020

Complement Activation Products and Cytokines in Pachychoroid Neovasculopathy and Neovascular Age-Related Macular Degeneration.

Yutaka Kato, Yasuharu Oguchi, Tomoko Omori, Hiroaki Shintake, Ryutaro Tomita, Akihito Kasai, Masashi Ogasawara, Yukinori Sugano, Kanako Itagaki, Akira Ojima and 3 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in Investigative ophthalmology & visual science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 28 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Yutaka KatoDepartment of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
Yasuharu OguchiDepartment of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
Tomoko OmoriDepartment of Immunology, Fukushima Medical University, Fukushima, Japan.
Hiroaki ShintakeDepartment of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
Ryutaro TomitaDepartment of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
Akihito KasaiDepartment of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
Masashi OgasawaraDepartment of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
Yukinori SuganoDepartment of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
Kanako ItagakiDepartment of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
Akira OjimaDepartment of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
Takeshi MachidaDepartment of Immunology, Fukushima Medical University, Fukushima, Japan.
Hideharu SekineDepartment of Immunology, Fukushima Medical University, Fukushima, Japan.
Tetsuju SekiryuDepartment of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
Fukushima Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To investigate the characteristics of complement activation products and angiogenic cytokines in the aqueous humor in eyes with pachychoroid neovasculopathy (PNV) and neovascular age-related macular degeneration (nAMD). Methods: This was a prospective, comparative, observational study. All patients with choroidal neovascularization were classified as PNV without polyps, PNV with polyps (polypoidal choroidal vasculopathy [PCV]), or drusen-associated nAMD according to the presence or absence of pachychoroid features and soft drusen. This study included a total of 105 eyes. Aqueous humor samples were collected from 25 eyes with PNV without polyps, 23 eyes with PCV, and 24 eyes with drusen-associated nAMD before intravitreal anti-vascular endothelial growth factor (VEGF) injection and cataract surgery in 33 control eyes. Clinical samples were measured for complement component 3a (C3a), C4a, C5a, VEGF, and macrophage chemoattractant protein 1 (MCP-1) using a bead-based immunoassay. Results: C3a and MCP-1 levels were significantly higher in PCV (P = 0.032 and P = 0.039, respectively) and drusen-associated nAMD (P = 0.01 for both comparisons) than in controls, and no difference was seen in C3a and MCP-1 levels between PNV and controls (P = 0.747 and P = 0.294, respectively). VEGF levels were significantly higher in PNV (P = 0.016), PCV (P = 0.009), and drusen-associated nAMD (P = 0.043) than in controls. In PNV, the VEGF levels elevated without elevated C3a and MCP-1. Conclusions: PNV, PCV, and drusen-associated nAMD had significantly distinct profiles of complement activation products and cytokines in the aqueous humor.

Indexed as

Angiogenesis InhibitorsAqueous HumorChoroidal NeovascularizationComplement ActivationCytokinesFemaleHumansIntravitreal InjectionsMaleProspective StudiesRetinal DrusenVascular Endothelial Growth Factor AWet Macular DegenerationAngiogenesis InhibitorsCytokinesVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID33252634
PMCPMC7705396
OpenAlexW3110462957

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.